Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Ch...(mors 5 cm; tamoxifen was given for 5 ye...),Health

Date:5/27/2008

mors > 5 cm; tamoxifen was given for 5 years to all patients with endocrine responsive tumors. A study amendment initiated during enrollment mandated the use of G-CSF with the first cycle of TAC, in order to reduce the incidence and severity of hematological toxicities and febrile neutropenia.

The primary end-point was DFS with analysis planned after a minimum follow-up of 5 years.

The full safety analysis has previously been published (Martin et al (2006), Ann Oncol 17: 1205-12). The analysis demonstrated that febrile neutropenia (grade 4) was the most common and clinically severe event (24.6%) reported with the TAC regimen. The incidence of febrile neutropenia decreased to 6.5% with the use of G-CSF from the first cycle of TAC. The incidence of febrile neutropenia among patients treated with FAC was 2.3%. Grade 2-4 anemia was higher in the TAC regimen (47.4%) vs FAC (7.5%). The incidence of anemia TAC decreased (27.5%) with the use of G-CSF. No toxic deaths were reported.

About Breast Cancer

According to the American Cancer Society, worldwide, breast cancer is the most common cancer in women and the second most common after lung cancer in both genders. More than one million new cases of breast cancer are reported worldwide annually and more than 400,000 women die each year from the disease.

In Europe, breast cancer is responsible for 27.3% of all new cancer cases among women and 20.22% of cancer deaths. The International Agency for Research in Cancer estimates that in 2004 there were 360,749 new breast cancer cases diagnosed while the number of deaths was 129,013.

According to the American Cancer Society, in general, breast cancer rates have risen about 30% in the past 25 years in western countries. In addition, the incidence is highest in western countries. This appears to be due to increased screening which detects breast cancer in earlier stages.

About GEICAM

GEICAM (Grupo Espanol de Investigacion en Cance
'/>"/>

SOURCE sanofi-aventis Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
2. Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination
3. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
4. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
5. Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors Visits
6. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
7. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
8. Gene Therapy Provides Vision to People who Were Nearly Blind
9. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
10. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
11. Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids